Style | Citing Format |
---|---|
MLA | Pakdel FD, et al.. "Investigating Interaction Between Il-17A, Il-17E, Tnf-Α and Rs3783605 and Its Effect on Vcam-1 Promoter Activity in the Human Umbilical Vein Endothelial Cells." Health Biotechnology and Biopharma, vol. 4, no. 1, 2021, pp. 59-67. |
APA | Pakdel FD, Pakdel JD, Tayebi L, Keramatipour M, Vodjgani M (2021). Investigating Interaction Between Il-17A, Il-17E, Tnf-Α and Rs3783605 and Its Effect on Vcam-1 Promoter Activity in the Human Umbilical Vein Endothelial Cells. Health Biotechnology and Biopharma, 4(1), 59-67. |
Chicago | Pakdel FD, Pakdel JD, Tayebi L, Keramatipour M, Vodjgani M. "Investigating Interaction Between Il-17A, Il-17E, Tnf-Α and Rs3783605 and Its Effect on Vcam-1 Promoter Activity in the Human Umbilical Vein Endothelial Cells." Health Biotechnology and Biopharma 4, no. 1 (2021): 59-67. |
Harvard | Pakdel FD et al. (2021) 'Investigating Interaction Between Il-17A, Il-17E, Tnf-Α and Rs3783605 and Its Effect on Vcam-1 Promoter Activity in the Human Umbilical Vein Endothelial Cells', Health Biotechnology and Biopharma, 4(1), pp. 59-67. |
Vancouver | Pakdel FD, Pakdel JD, Tayebi L, Keramatipour M, Vodjgani M. Investigating Interaction Between Il-17A, Il-17E, Tnf-Α and Rs3783605 and Its Effect on Vcam-1 Promoter Activity in the Human Umbilical Vein Endothelial Cells. Health Biotechnology and Biopharma. 2021;4(1):59-67. |
BibTex | @article{ author = {Pakdel FD and Pakdel JD and Tayebi L and Keramatipour M and Vodjgani M}, title = {Investigating Interaction Between Il-17A, Il-17E, Tnf-Α and Rs3783605 and Its Effect on Vcam-1 Promoter Activity in the Human Umbilical Vein Endothelial Cells}, journal = {Health Biotechnology and Biopharma}, volume = {4}, number = {1}, pages = {59-67}, year = {2021} } |
RIS | TY - JOUR AU - Pakdel FD AU - Pakdel JD AU - Tayebi L AU - Keramatipour M AU - Vodjgani M TI - Investigating Interaction Between Il-17A, Il-17E, Tnf-Α and Rs3783605 and Its Effect on Vcam-1 Promoter Activity in the Human Umbilical Vein Endothelial Cells JO - Health Biotechnology and Biopharma VL - 4 IS - 1 SP - 59 EP - 67 PY - 2021 ER - |